PITTSBURGH--(BUSINESS WIRE)--invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its DiaryPRO® field-based ePRO system was used to capture primary efficacy endpoint data in the recently unblinded Phase III study of Pollinex® Quattro, a vaccine being developed by Allergy Therapeutics® plc (AIM:AGY) to treat the symptoms of seasonal allergic rhinoconjunctivitis (SAR).
